Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 12 Nov 2019

The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.

23 Sep 2019
Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine, appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.

Product Highlight - Benlysta

20 Dec 2019
Adding BENLYSTA to standard therapy:
• Superior reduction in SLE disease activity1*†‡
• Reduction in corticosteroid dose in patients on >7.5 mg/day at baseline1#
• Severe flare risk reduction by 50%1
• Significant improvement in fatigue as early as Week 82^
• Rates of adverse events were similar between BENLYSTA and placebo1-3*

Remarks: * Defined as positive anti-dsDNA (≥30 IU/mL) and low C3 and/or C4 complement. Standard therapies permitted, alone or in combination: corticosteroids, immunosuppressants, antimalarials, and NSAIDs. BLISS-52 and BLISS-76 pooled data. # Reduction to ≤7.5 mg/day: 24.6% vs 15.0% (p = 0.035).
^ FACIT-Fatigue score improvement at Week 52: 4.07 vs 1.80 (p = 0.004).

References:
1. Benlysta SC Prescribing Information version GDS15.
2. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-1349.
3. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 12 Nov 2019

The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.

23 Sep 2019
Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine, appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.